For nearly a decade, the Cancer Dependency Map (DepMap) at the Broad Institute of MIT and Harvard has served as the "periodic table" of cancer research. By systematically identifying the specific genetic vulnerabilities that tumors rely on to survive, the project has provided the pharmaceutical industry and academic researchers with a roadmap for precision medicine. Now, in a transformative expansion, scientists have integrated 3D cancer models—organoids and spheroids—into the DepMap, effectively bridging the gap between flat lab cultures and the complex, three-dimensional reality of human tumors.
This expansion, detailed in a major study published in Nature, marks a shift in how the scientific community approaches drug discovery. By incorporating nearly 150 3D models across 10 distinct cancer types, the DepMap team has created a more holistic resource, revealing biological mechanisms that have remained hidden in traditional, two-dimensional (2D) cell cultures.
The Chronology of a Scientific Milestone
The journey toward a comprehensive map of cancer vulnerabilities began in 2018 with the formal launch of the DepMap Consortium. This academic-industry partnership was built on a simple yet profound premise: if researchers could systematically "turn off" genes across hundreds of cancer cell lines, they could identify which genes were essential for a tumor’s survival—its "dependencies."
From 2D Foundations to 3D Complexity
Initially, the DepMap focused almost exclusively on traditional 2D cell lines—cells grown on flat plastic surfaces. While these models have been the workhorses of oncology research for decades, they possess inherent limitations. When cells are flattened against a plastic dish, they often lose the intricate architecture and microenvironmental signals present in actual human tumors.
Recognizing these limitations, the scientific community began developing "next-generation" models: organoids and spheroids. These are 3D clusters of cells, often grown in gel or suspended in specialized media, that more closely mimic the behavior, structure, and genetic heterogeneity of patient tumors. However, for years, these 3D models were used sporadically in isolated labs. There was no standardized, large-scale catalog of their genetic dependencies.
To address this, the DepMap team undertook a massive effort to gather patient-derived organoids from global collaborators and commercial suppliers. Over several years, they subjected these models to the same rigorous, genome-wide CRISPR screening processes used for 2D lines. The result is the current, expanded DepMap, which now allows researchers to compare the biological behavior of 2D and 3D models side-by-side, creating a unified, data-rich landscape for discovery.
Supporting Data: Why 3D Matters
The integration of 3D models is not merely an aesthetic update; it provides fundamentally different data. The study reveals that the physical environment in which a cancer cell is grown significantly dictates its genetic dependencies.
Decoding the Microenvironment
One of the most significant findings in the new study is the distinction between how growth format and culture medium influence cell behavior. Through their analysis, the team identified two major drivers of dependency changes:
- Cell Adhesion and Cytoskeleton: Genes involved in how cells stick to one another and maintain their structural integrity were found to be highly sensitive to the growth format (3D vs. 2D).
- Lipid Metabolism: Genes related to how cells process fats were found to be sensitive to the chemical composition of the culture medium, independent of whether the cells were in 3D or 2D.
These insights provide a "rulebook" for researchers, helping them determine which model type is best suited for their specific scientific question.
Striking Examples of New Vulnerabilities
The clinical implications of this data are already apparent. In the case of glioblastoma—an aggressive and often lethal form of brain cancer—the team identified a key vulnerability. Models lacking the tumor-suppressor gene CDKN2A were significantly more sensitive to the inhibition of CDK6, a protein kinase. This discovery suggests that CDKN2A status could serve as a vital biomarker for identifying which glioblastoma patients might respond to existing CDK6-targeted therapies, a level of precision that was obscured in traditional 2D models.
Similarly, in pancreatic and gastrointestinal organoids, researchers identified a specific gene expression program that disappears in traditional 2D cell lines but persists in 3D organoids. These 3D-specific cells were uniquely dependent on WNT signaling genes. This finding unveils a potential therapeutic "Achilles’ heel" for a specific subtype of pancreatic cancer that would have remained invisible in standard laboratory conditions.
Official Perspectives: The "Complementary" Future
The expansion of DepMap was a massive collaborative undertaking, reflected in the fact that the primary study appears alongside two companion papers in Nature—one led by the National Cancer Institute’s Human Cancer Models Initiative and the Dana-Farber Cancer Institute, and another by the Wellcome Sanger Institute.
Francisca Vazquez, director of the Cancer Dependency Map and co-senior author of the study, emphasized that the goal is not to replace 2D models, but to diversify the toolkit available to scientists.
"These models let us see biology that we couldn’t see before," Vazquez stated. "That is the whole point of DepMap. The more aspects of each tumor you capture, the more of its vulnerabilities you can catch."
Vazquez and her colleagues, including co-corresponding author Tsukasa Shibue and co-first authors James Neiswender, Samuel Maffa, and Lisa Brenan, argue that 2D and 3D models are inherently complementary. In some instances, such as certain breast cancer subtypes, the 2D models actually retain markers that are lost in 3D culture. Therefore, the "complete map" that the Broad Institute envisions is one that incorporates the unique strengths of every available model.
Implications for Precision Medicine
The implications for the future of oncology are profound. By providing a comprehensive, cross-referenced, and publically accessible database, the DepMap is accelerating the pipeline from basic biology to the clinical trial.
Bridging the "Translation Gap"
For years, the "translation gap"—the failure of drugs that show promise in the lab to work in human patients—has been a major bottleneck in cancer research. By better modeling the 3D architecture of tumors, the DepMap team is helping to filter out ineffective drug candidates earlier in the research cycle, while identifying promising targets that are more likely to translate to clinical success.
A Community-Driven Resource
The DepMap portal is now open for researchers worldwide to explore this expanded dataset. By democratizing access to this information, the Broad Institute is encouraging a global effort to decode cancer’s complex dependencies. Whether it is a researcher studying the metabolic quirks of a rare brain tumor or a pharmaceutical scientist looking for a new target in gastrointestinal cancer, the expanded DepMap provides a foundation that is grounded in biological reality rather than convenience.
Moving Toward a Complete Map
The mission of the DepMap has always been ambitious: to map the dependencies that drive every type of cancer. The inclusion of 150 3D models is a massive step forward, but the team acknowledges that the work is far from finished. As new technologies—such as CRISPR-Cas9 screening in increasingly complex organoid systems—evolve, the DepMap will continue to grow.
The message from the research community is clear: cancer is not a static disease, and the models used to study it must be just as dynamic. By embracing the complexity of 3D biology, the Cancer Dependency Map has solidified its role as an indispensable pillar of modern medical research. As these findings move into clinical application, the promise of truly personalized, highly effective cancer treatments feels more attainable than ever before. For researchers, the path forward is now clearer, mapped by the very dependencies that once allowed these cancers to thrive, but which may now lead to their undoing.
About the Author
